STRONGBRIDGE BIOPHARMA plc Comprehensive Income
STRONGBRIDGE BIOPHARMA plc reported Comprehensive Income of -$13.24 million for the 3-month period ending 2021-06-30, per its 10-Q filed 2021-08-05.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2021-08-05
- STRONGBRIDGE BIOPHARMA plc comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2021-06-30 was -$13.24M.
- STRONGBRIDGE BIOPHARMA plc comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2021-03-31 was -$11.81M.
- STRONGBRIDGE BIOPHARMA plc comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2020-12-31 was -$11.95M.
- STRONGBRIDGE BIOPHARMA plc comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2020-09-30 was -$3.16M.
- STRONGBRIDGE BIOPHARMA plc comprehensive income (loss), net of tax, attributable to parent for fiscal 2020 was -$45.08M.
- STRONGBRIDGE BIOPHARMA plc comprehensive income (loss), net of tax, attributable to parent for fiscal 2019 was -$49.45M, a 255.25% decline from fiscal 2018.
- STRONGBRIDGE BIOPHARMA plc comprehensive income (loss), net of tax, attributable to parent for fiscal 2018 was $31.85M.
- STRONGBRIDGE BIOPHARMA plc comprehensive income (loss), net of tax, attributable to parent for fiscal 2017 was -$113.48M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2021-06-30 | -$13.24M 10-Q · filed 2021-08-05 | -$25.05M 10-Q · filed 2021-08-05 | -$37.00M derived: sum of 3 quarters · filed 2021-08-05 | -$40.16M derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | -$11.81M 10-Q · filed 2021-05-12 | -$23.76M derived: sum of 2 quarters · filed 2021-05-12 | -$26.92M derived: sum of 3 quarters · filed 2021-05-12 | -$44.20M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-12-31 | -$11.95M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | -$15.11M derived: sum of 2 quarters · filed 2021-03-03 | -$32.38M derived: sum of 3 quarters · filed 2021-08-05 | -$45.08M 10-K · filed 2021-03-03 |
| 2020-09-30 | -$3.16M 10-Q · filed 2020-10-29 | -$20.44M derived: sum of 2 quarters · filed 2021-08-05 | -$33.13M 10-Q · filed 2020-10-29 | -$42.11M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-06-30 | -$17.28M 10-Q · filed 2021-08-05 | -$29.97M 10-Q · filed 2021-08-05 | -$38.95M derived: sum of 3 quarters · filed 2021-08-05 | -$52.74M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | -$12.70M 10-Q · filed 2021-05-12 | -$21.67M derived: sum of 2 quarters · filed 2021-05-12 | -$35.46M derived: sum of 3 quarters · filed 2021-05-12 | -$43.71M derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | -$8.98M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-03 | -$22.77M derived: sum of 2 quarters · filed 2021-03-03 | -$31.01M derived: sum of 3 quarters · filed 2021-03-03 | -$49.45M 10-K · filed 2021-03-03 |
| 2019-09-30 | -$13.79M 10-Q · filed 2020-10-29 | -$22.04M derived: sum of 2 quarters · filed 2020-10-29 | -$40.47M 10-Q · filed 2020-10-29 | |
| 2019-06-30 | -$8.25M 10-Q · filed 2020-08-04 | -$26.68M 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | -$18.43M 10-Q · filed 2020-05-06 | |||
| 2018-12-31 | $31.85M 10-K · filed 2021-03-03 | |||
| 2017-12-31 | -$113.48M 10-K · filed 2020-02-28 | |||
| 2016-12-31 | -$16.00M derived: 20-F 12 month − 6-K 9 month · filed 2017-04-04 | -$23.60M derived: sum of 2 quarters · filed 2017-04-04 | -$36.44M derived: sum of 3 quarters · filed 2017-04-04 | -$48.60M 20-F · filed 2017-04-04 |
| 2016-09-30 | -$7.60M 6-K · filed 2016-12-30 | -$20.44M derived: sum of 2 quarters · filed 2016-12-30 | -$32.60M 6-K · filed 2016-12-30 | -$43.00M derived: sum of 4 quarters · filed 2017-04-04 |
| 2016-06-30 | -$12.84M 6-K · filed 2016-12-30 | -$25.00M 6-K · filed 2016-12-30 | -$35.40M derived: sum of 3 quarters · filed 2017-04-04 | -$45.06M derived: sum of 4 quarters · filed 2017-04-04 |
| 2016-03-31 | -$12.15M 6-K · filed 2016-05-17 | -$22.56M derived: sum of 2 quarters · filed 2017-04-04 | -$32.22M derived: sum of 3 quarters · filed 2017-04-04 | -$49.36M derived: sum of 4 quarters · filed 2017-04-04 |
| 2015-12-31 | -$10.41M derived: 20-F 12 month − 6-K 9 month · filed 2017-04-04 | -$20.06M derived: sum of 2 quarters · filed 2017-04-04 | -$37.21M derived: sum of 3 quarters · filed 2017-04-04 | -$43.58M 20-F · filed 2017-04-04 |
| 2015-09-30 | -$9.66M 6-K · filed 2016-12-30 | -$26.80M derived: sum of 2 quarters · filed 2016-12-30 | -$33.17M 6-K · filed 2016-12-30 | |
| 2015-06-30 | -$17.14M 6-K · filed 2016-12-30 | -$23.52M 6-K · filed 2016-12-30 | ||
| 2015-03-31 | -$6.37M 6-K · filed 2016-05-17 | |||
| 2014-12-31 | -$9.67M 20-F · filed 2017-04-04 | |||
| 2013-12-31 | -$5.29M 20-F · filed 2016-03-24 |